Academic literature on the topic 'Cancers poumon et sein'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancers poumon et sein.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Cancers poumon et sein":
Kachuri, L., P. De, LF Ellison, and R. Semenciw. "Tendances concernant l'incidence du cancer, la mortalité par cancer et la survie au cancer au Canada entre 1970 et 2007." Maladies chroniques et blessures au Canada 33, no. 2 (March 2013): 80–92. http://dx.doi.org/10.24095/hpcdp.33.2.03f.
Wagner, Anna Dorothea, Khalil Zaman, Solange Peters, and Michael Montemurro. "Traitements [b]antiangiogéniques[/b] des cancers métastatiques du côlon et du rectum, du sein et du poumon : bénéfices et risques." Revue Médicale Suisse 6, no. 250 (2010): 1070–73. http://dx.doi.org/10.53738/revmed.2010.6.250.1070.
Kouassy, KY, O. Kimso, K. Traore, BA Oddo, A. Edoukou, DR Niang, KA Gaetan, SI Mounkeila, M. Toure, and I. Adoubi. "C103: Intérêt du Paclitaxel – Bévacizumab dans le cancer du sein triple négatif métastatique à Abidjan." African Journal of Oncology 2, no. 1 Supplement (March 1, 2022): S43. http://dx.doi.org/10.54266/ajo.2.1s.c103.jsle2071.
Giraud, P., J. Djadi-Prat, E. Morvan, M. Morelle, R. Remmonay, N. Pourel, C. Durdux, et al. "Intérêts dosimétriques et cliniques de la radiothérapie asservie à la respiration des cancers du poumon et du sein : résultats du Stic 2003." Cancer/Radiothérapie 16, no. 4 (July 2012): 272–81. http://dx.doi.org/10.1016/j.canrad.2012.03.005.
Berlivet, Luc. "Les médecins, le tabagisme et le Welfare State: Le gouvernement britannique face au cancer (1947-1957)." Annales. Histoire, Sciences Sociales 65, no. 1 (February 2010): 157–90. http://dx.doi.org/10.1017/s0395264900026238.
Wanigaratne, S., E. Holowaty, H. Jiang, TA Norwood, R. Pietrusiak, and R. Brown. "Estimation du risque de cancer lié à l'exposition au tritium dans le cadre des activités courantes de la centrale nucléaire de Pickering (Ontario)." Maladies chroniques et blessures au Canada 33, no. 4 (September 2013): 278–89. http://dx.doi.org/10.24095/hpcdp.33.4.06f.
Keita, M., A. Toure, I. Camara, A. Barry, M. Koulibaly, and B. Traore. "C98: Impact de la chirurgie associée à la radiothérapie sur le pronostic du cancer du sein en Guinée : Etude cohorte des cancers du sein de Guinée." African Journal of Oncology 2, no. 1 Supplement (March 1, 2022): S41—S42. http://dx.doi.org/10.54266/ajo.2.1s.c98.jdql5963.
Latorzeff, I., C. Bourgier, B. Pinel, C. Hennequin, G. Jimenez, O. Chapet, and X. Zasadny. "Traitement de la maladie primitive (cancers du sein, du poumon non à petites cellules et de la prostate), par irradiation, au stade d’emblée métastatique." Cancer/Radiothérapie 23, no. 6-7 (October 2019): 486–95. http://dx.doi.org/10.1016/j.canrad.2019.08.004.
Mané, M., AS Koné, J. Nguessan, A. Ayémou, AA Kassé, MM Dieng, and PM Gaye. "C104: Arcthérapie volumétrique synchrone dans le cancer du sein bilatéral : Première expérience au Sénégal : A propos de deux cas." African Journal of Oncology 2, no. 1 Supplement (March 1, 2022): S43—S44. http://dx.doi.org/10.54266/ajo.2.1s.c104.xjsr1627.
Bousquet, P. J., P. Caillet, M. Coeuret-Pellicer, H. Goulard, Y. C. Kudjawu, C. Le Bihan, A. I. Lecuyer, and F. Séguret. "Recherche d’algorithmes d’identification des cancers dans les bases médico-administratives : premiers résultats des travaux du groupe REDSIAM Tumeurs sur les cancers du sein, du côlon-rectum et du poumon." Revue d'Épidémiologie et de Santé Publique 65 (October 2017): S236—S242. http://dx.doi.org/10.1016/j.respe.2017.04.057.
Dissertations / Theses on the topic "Cancers poumon et sein":
Soussan, Michaël. "Developpement et applications cliniques de methodes de quantification en TEP pour le pronostic et le suivi therapeutique des cancers." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA112135.
In the era of personalized medicine, genomics and targeted therapies, the availability of quantitative tools assisting the interpretation of medical images is essential. In Positron Emission Tomography (PET), beyond measurements of uptake intensity, it is possible to derive quantitative index characterizing the metabolic volume or the tumoral heterogeneity. The objective of this work was to investigate the value of new quantitative indices to enhance PET imaging, allowing for a more comprehensive analysis of the whole tumor. The first part of the work deals with methodological issues associated with the measurement of tumor heterogeneity using textural index. In particular, we identified the most robust and informative textural index for clinical applications. Two sets of patients have then been used to explore the contribution of metabolic volume and texture analysis in PET. In lung cancer patients, our results suggest that the measurement of tumor heterogeneity gives some information regarding the histological features of the tumor. A second set of results shows that metabolic volume is more relevant than conventional indices for evaluating the impact of neoadjuvant chemotherapy in locally advanced stages. A correlation between quantitative changes during treatment and post-treatment histology results was used to demonstrate the relevance of these indices. In breast cancer patients, our results suggest that tumors with aggressive immunohistological patterns, particularly triple-negative phenotype, have a more heterogeneous texture than other types. In summary, our results suggest that a more comprehensive quantitative characterization of the metabolic activity distribution in tumor using PET imaging improves the pre-therapeutic and prognostic evaluation of cancer
Chaisemartin, Luc de. "Etude de l’organisation et des fonctions des lymphocytes T au sein des structures lymphoïdes tertiaires dans le cancer pulmonaire." Paris 6, 2010. http://www.theses.fr/2010PA066684.
El, Kadiri Hanae. "Mise en évidence de l'activité antitumorale du taxol au moyen de tests in vitro sur cellules humaines : cancers bronchiques à petites cellules (lignée NCI-N 417), de l'ovaire et du sein." Université Joseph Fourier (Grenoble), 1988. http://www.theses.fr/1988GRE18002.
Toullec, Alexis. "Dispositif d’aiguille fibrée pour la spectroscopie de fluorescence endogène de lésions mammaires et pulmonaires ex vivo et in vivo ; vers le développement d'une méthode d’ histopathologie in situ." Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS154/document.
The third Cancer Plan, launched in 2013, identifies early diagnosis as one of the major challenges for improving patient care. Despite the growth in medical imaging modalities and performance, challenges remain in diagnosis aid and optimizing the use of biopsy.Photonic imaging and especially spectrally resolved fluorescence has already been tested for the ex vivo characterization of breast and lung tumors, without contrast agent or sample processing. Our goal is to characterize the capabilities of an innovative medical device, developed in the laboratory, using a low-caliber fibered needle for the spectral analysis of the endogenous fluorescence of these lesions in situ. Our early work in preclinical and clinical studies showed significant differences in spectral signatures between benign and malignant tumors ex vivo and in vivo. Our results also highlighted the limits the device, in terms of specificity, for certain types of lesions.Another study was conducted on mammary tumors in order to identify the major tissue entities at the origin of the spectral signatures obtained with our fibered device. Spectral imaging in confocal and second harmonic microscopy (SHG), in multiphoton, has been implemented in order to establish a mapping of endogenous biomarkers of mammary tissues. We compare its results with the data obtained with the fibered needle device in order to position it not only as an aid to diagnosis but also as a promising method for in situ histopathology
Marchand, Anne. "Reconnaissance et occultation des cancers professionnels : le droit à réparation à l'épreuve de la pratique (Seine-Saint-Denis)." Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLE005.
Cancerous pathologies, currently the leadingcause of death in France, are also one of the main causes of social inequalities before death. The importance of occupational factors in the onset of the disease remains largely under-estimated, particularly because very few cancr patients exercise their right to compensation for occupational diseases, a phenomenon officially described as "under-reporting" and "under-recognition". This research, which has benefited from data collected by a program designed to identify and support occupational-cancer patients implemented since 2002 in the French département of Seine-Saint-Denis by the the French "Groupement d'Intérêt Scientifique sur les Cancers d'Origine Professionnelle" (ie GISCOP93, a scientific association for occupational cancers), set out to monitor current and former workers and employees who have been diagnosed with broncho-pulmonary cancer as well as their families, as they go through the process of seeking and obtaining compensation, in order to identify the factors that determine whether they do or do not exercise their rights. This research, based on the data gathered during this phase of ethnographical research, on archival holdings and on observations in a French "Caisse primaire d'assurance maladie" (CPAM, ie local healthcare insurance office), comprises three parts. After describing the research protocol that was implemented, the first part focuses on identifying the conditions required for occupational-cancer patients, to exercise their rights: they need to learn to perceive themselves as "victims" of their occupational history and to find the resources necesary to start the compensation-seeking process. The second part focuses on retracing the history of the medical and legal category of occupational cancer, which was first defined in the early 20th century, and more specifically, on the history of broncho-pulmonary cancers. This part describes the conditions which led to creating the notion of "presumed origin" - a cornerstone of the occupational-harm reparation system - in the case of this specific type of cancer. By retracing the stages of evolution of a table of occupational diseases from the early 1920s to the early 1990s, it illustrates how fragile this last category can be. The third section records what happens when the right to compensation is enforced by the institution in charge of investigating claims, revealing what takes place behind the scènes during the investigation of a claimand the conditions that define whether and when a case of cancer is recognized as an occupational disease
Bennis, Fai͏̈za. "Etude de la 3-hydroxy-3-méthylglutaryl coenzyme à réductase dans la lignée d'adénocarcinome pulmonaire humain A5449 : régulation et implication dans la croissance cellulaire." Toulouse 3, 1993. http://www.theses.fr/1993TOU30263.
Ortholan-Nègre, Cécile. "Approche translationnelle du concept de cible en cancérologie : étude de l'effet combiné du Docetaxel et du Bevacizumab sur la boucle autocrine VEGF / VEGF-R2 dans des modèles cellulaires de cancer du sein et de la prostate : étude d'une signature microARN pronostique dans les adénocarcinomes du poumon de stade I." Nice, 2010. http://www.theses.fr/2010NICE4083.
Targeted therapies are and important part of cancer treatment. Oncologist may have an overview of potential targets, and may understand the synergic effect of chemotherapies and targeted therapies. Tumor neoangiogenesis represent a critical step in tumor development. Main anti angiogenesis targeted therapy is Bevacizumab, which is a monoclonal antibodies inhibiting the binding VEGF (vascular endothelial growth factor) to its receptor. Docetaxel is one of the most important chemotherapy in cancer treatment. It inhibits microtubule depolymerisation. In breast and prostate cancer, Docetaxel delivered in association with Bevacizumab increases tumor response compared with Docetaxel alone. In this work, we investigated the combined effect of both treatments on the VEGF / VEGF-R2 autocrine loop, in breast and prostate cancer cells. We have demonstated that, in standard condition, the VEGF / VEGF-R2 loop is redundant in terms of cell survival. However, when cells are treated with Docetaxel, main growth pathways are inhibited: then, the VEGF / VEGF-R2 autocrin,e loop is useful for cell survival. The addition of Bevacizumab to Docetaxel inhibits the autocrine loop by decreasing extracellular VEGF and membrane expression of VEGF-R2, leading to cell proliferation arrest. Then, inthis work, we propose a new explanation for the synergiec effect of Taxane and Bevacizumab on tumor cells. Another approach in the understanding of targeted therapy action is the identification of prognostic and therapeutic targets. In the second part of this work, we have investigated the microRNA expression pattern of 27 stage I lung adenocarcinomas. By screening microRNA expression on microchip, we have highlighted the presence of a prognostic signature, predicting cancer outcome : under expression of mir99a and mir30a, over expression of mir 297 and mir 21. The signature is under validation on a large series of patient. As a conclusion, both parts of this work investigate two aspects of the target concept in oncology, by studying mechanism of synergy between a targeted therapy and chemotherapy, and by searching new targets such as microRNA
Ducrot, Lucas. "Réseaux bayésiens et analyse de survie pour l’estimation de courbes de pénétrance du cancer broncho-pulmonaire lié à des prédispositions génétiques." Electronic Thesis or Diss., Sorbonne université, 2024. http://www.theses.fr/2024SORUS055.
This thesis focuses on estimating penetrance curves of genetic diseases from pedigree data, with a particular interest in the genetic predisposition to bronchopulmonary cancer. In this context, it aims to provide clinical and epidemiological results, as well as methodological findings.Genetic counselling is offered to patients with severe family histories of genetic diseases. Geneticists must select from these patients who should be offered genetic testing, and assess the disease risks for these patients and their families. Advances in genetics are rapid, and the number of identified pathogenic variants for different diseases increases each year. This necessitates significant predictive and risk assessment tools, especially in the context of bronchopulmonary cancer. Indeed , the links between the latter and pathogenic variants (such that SFTPA1/SFTPA2 and the genes TP53 and EGFR) are known but still poorly described.Existing methods for assessing the risk of disease occurrence rely on penetrance curves, but their estimation faces challenges due to the small number of patients and the omnipresent selection bias in genetics-collected datasets. To overcome these obstacles, the thesis explores the use of familial data, employing a set of statistical tools including Bayesian networks, mixture models, survival analysis, as well as existing models, for which it attempts to weaken certain assumptions.Chapter 1 provides an overview of the medical context of the thesis, introducing the concepts of genetic diseases and genetic counseling. Chapter 2 serves as a methodological introduction, presenting and illustrating concepts such as survival analysis, Bayesian networks, sum-product algorithm, mixture models and EM algorithm, using examples. It also offers a state-of-the-art review of penetrance curve estimation for genetic diseases and highlights the selection bias in genetics. The chapter concludes with a summary of the addressed research questions.Then, the thesis revolves around four projects. The first two projects, corresponding to chapters 3 and 4, offer predominantly clinical and epidemiological results. The first project, described in Chapter 3, compares different methods for predicting pathogenic variants for breast/ovarian cancers (Manchester Score and family models like BOADICEA). The second project, addressed in Chapter 4, provides estimates of penetrance for interstitial lung disease and bronchopulmonary cancer for carriers of pathogenic variants SFTPA1 and SFTPA2.The last two projects, corresponding to chapters 5 and 6, are more methodological. Chapter 5 is dedicated to developing a new method for estimating the penetrance curve of a genetic disease from pedigree data when the disease presents sporadic cases. It is based on an incidence constraint of the disease in the general population and a parameterization of the relative hazard between carriers and non-carriers of pathogenic variants. Chapter 6 focuses on highlighting the bias introduced by selection in genetics and its consequences on the results of the method developed in Chapter 5. Known correction methods, such as Proband's Phenotype Exclusion Likelihood (PEL) and Genotype-Restricted Likelihood (GRL), combined with our method, are applied to simulated data
Mombelli, Sarah. "Cancers du sein et immunité anti-tumorale." Thesis, Reims, 2014. http://www.theses.fr/2014REIMS041/document.
With around 49 000 new affected women each year, breast cancer is the most common of feminine cancers. Breast cancer screening, and treatments improvements make mortality decreased but it stays the most murderous of feminine cancers in France.Breast cancer being a heterogeneous disease, individualizing patients' treatments is now one of first goals of practitioner. It is around of this common aim that my 2 thesis projects are turned on.On the one side, for clinical study, I designed a database on the neoadjuvant strategy of operable breast cancers, assembling 318 patients treated at Jean Godinot institute. This database allow us to compare our results with literature ones, to highlight the interest of neoadjuvant chemotherapy to determine new prognostic factors, and to validate evaluation of residual disease in breast and nodes by RDBN index.On the other side experimental study allowed us to improve our knowledge on molecular mechanisms of tumor escape. We demonstrated pro-tumoral role of IL-17A but also of IL-17E, these two cytokines can be presents in tumoral microenvironment, and evidenced their implication in cell cycle dysregulation through generation of LMW-E and acquisition of chemoristance mechanisms
Martin, Marie-Claude. "Cancers broncho-pulmonaires primitifs chez les sujets de 75 ans et plus." Bordeaux 2, 1999. http://www.theses.fr/1999BOR2M111.
Books on the topic "Cancers poumon et sein":
Descamps, Philippe. Dépistage des cancers gynécologiques et mammaires. Paris: Masson, 2004.
Guessan, L. N'. Comment éliminer le Cancer du Sein, du Poumon et d'autres, Avec une Plante: Medecine Chinoise. Independently Published, 2020.
Book chapters on the topic "Cancers poumon et sein":
Fumoleau, P. "RBU et cancers du sein métastatiques." In Cancer du sein en situation métastatique, 463. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_41.
Guiu, S., B. Coudert, and P. Fumoleau. "Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs." In Cancer du sein, 499–528. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_33.
Ancelle-Park, R. "Le dépistage organisé des cancers du sein, 20 ans après: Bénéfices et controverses." In Cancer du sein, 197–202. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_15.
Guastalla, J. P., O. Trédan, J. Peron, S. I. Labidi-Galy, P. Heudel, I. Ray-Coquard, and T. Bachelot. "Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications." In Cancer du sein, 553–64. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_35.
de Cremoux, Patricia. "Marqueurs pronostiques et prédictifs des cancers du sein précoces." In Diagnostic et décision dans le cancer du sein à un stade précoce, 41–49. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0253-4_3.
Rouanet, P. "Chirurgie de rattrapage des cancers du sein localement évolués et des récidives locales agressives." In Cancer du sein avancé, 217–25. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-72615-6_22.
Delozier, T., O. Switsers, J. M. Ollivier, C. Lévy, A. Rivière, D. Allouache, C. Delcambre, P. Berthet, and K. Gunzer. "Évolution de l’histoire naturelle et du pronostic des métastases des cancers du sein sur quatre décennies Étude de 4 110 cancers du sein métastasés." In Cancer du sein avancé, 131–37. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-72615-6_13.
Thibault, F. "Place de l’IRM mammaire dans la prise en charge des cancers du sein: Information morphologique et fonctionnelle." In Cancer du sein, 277–81. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_22.
Lacroix-Triki, M., J. F. Dupuy, F. Dalenc, S. Dejean, P. Besse, H. Roché, and S. Vagner. "Altérations de l’expression, et implications pronostique et thérapeutique, des protéines régulatrices de l’épissage des ARNm dans les cancers du sein." In Cancer du sein avancé, 253–55. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-72615-6_27.
Séradour, B. "Dépistage des cancers du sein : les cancers de l’intervalle du programme français Définitions — Particularités." In Acquis et limites en sénologie / Assets and limits in breast diseases, 307–10. Paris: Springer Paris, 2013. http://dx.doi.org/10.1007/978-2-8178-0396-8_51.